Biovie Inc.
BIVIW- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001580149
In the last 90 days, Biovie Inc. insiders filed 5 open-market purchases and 0 sales; 8 institutions reported holding it in 13F filings for Q2 2026, worth $1.07M in total; no superinvestor holds it.
Other share classesBIVI
Key figures
- Market capClose on Nov 17, 2026
- $10.7M
- Insider buysLast 90 days, $52.0K in total
- 5
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, 0 vs. previous quarter
- 8
- 13F valueReported value at the end of Q2 2026
- $1.07M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2026
- –
- No comparable prior period
- Net income, FY2026
- -$22.1M
- No comparable prior period
- Free cash flow, FY2026
- –
- No comparable prior period
- Revenue, Q1 FY2027
- –
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 50.4K
- Shares sold short
- Change
- +20.4K
- +67.7% vs. previous
- Days to cover
- 2.24
- At average daily volume
Superinvestors holding BIVIW, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding BIVIW at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Biovie Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 16, 2026 (view filing)4:30 PM ET | Nov 13 | 3 days | Do Cuong VPresident & CEO | PPurchase | +2.50K | $1.16 | +$2.91K | +15.5%18.6K after | |
| Aug 28, 2026 (view filing)9:01 PM ET | Aug 28 | Same day | Palumbo Joseph MChief Medical Officer | PPurchase | +4.84K | $2.16 | +$10.5K | +406.0%6.04K after | |
| Aug 28, 2026 (view filing)9:01 PM ET | Aug 28 | Same day | Chappell Amy SuzonDirector | PPurchase | +727 | $2.16 | +$1.57K | New position727 after | |
| Aug 28, 2026 (view filing)8:58 PM ET | Aug 28 | Same day | Kim Joanne WendyChief Financial Officer | PPurchase | +2.50K | $2.18 | +$5.45K | +265.7%3.44K after | |
| Aug 28, 2026 (view filing)8:57 PM ET | Aug 27 | 1 day | Do Cuong VPresident & CEO | PPurchase | +15.2K | $2.08 | +$31.6K | +1,677.0%16.1K after | |
| Aug 13, 2025 (view filing) | Aug 7 | 6 daysLate | Do Cuong VPresident & CEO | PPurchase | +5.00K | – | – | +100.2%9.99K after | |
| Aug 13, 2025 (view filing) | Aug 7 | 6 daysLate | Do Cuong VPresident & CEO | PPurchase | +5.00K | – | – | –5.05K after | Derivative |
| Mar 6, 2024 (view filing) | Mar 4 | 2 days | Do Cuong VPresident & CEO | PPurchase | +10.0K | – | – | +2.3%435.9K after | |
| Mar 6, 2024 (view filing) | Mar 4 | 2 days | Do Cuong VPresident & CEO | PPurchase | +5.00K | – | – | –5.00K after | Derivative |
| Dec 6, 2023 (view filing) | Dec 1 | 5 daysLate | Gorlin SteveDirector | SSale | −75.7K | $1.69 | −$127.9K | −62.0%46.4K after |
Top 10 13F holders, Q2 2026
See all 8 holdersThe largest institutional positions in Biovie Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Diametric Capital, LP | 750,000 | $337.5K | 0.04% | 00.0% | Unchanged |
| Warberg Asset Management LLC | 613,426 | $276.0K | 0.08% | +156,797+34.3% | Added |
| Armistice Capital, LLC | 500,000 | $225.0K | 0.01% | 00.0% | Unchanged |
| Prelude Capital Management, LLC | 186,621 | $84.0K | 0.01% | 00.0% | Unchanged |
| MYDA Advisors LLC | 159,800 | $71.9K | 0.02% | −9,113−5.4% | Reduced |
| Heights Capital Management, Inc | 90,000 | $40.5K | 0.01% | 00.0% | Unchanged |
| Armstrong Advisory Group, Inc | 65,900 | $29.7K | 0.00% | 00.0% | Unchanged |
| Two Sigma Securities, LLC | 13,884 | $6.25K | 0.00% | +2,750+24.7% | Added |